We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Testing Method Predicts Trauma Patient Recovery Days in Advance

By LabMedica International staff writers
Posted on 16 Feb 2026

Trauma patients with nearly identical injuries often experience very different recoveries, even when treated similarly. More...

Traditional assessments based on injury severity do not always explain why some patients develop organ failure or die while others recover. This unpredictability limits doctors’ ability to intervene early and tailor care. Now, a new study shows that analyzing molecular signals in blood can predict recovery trajectories and complications days before they appear.

Researchers at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a first-of-its-kind study using “omics” technologies, combining proteomics and metabolomics to examine biological signals in trauma patients’ blood. The team mapped molecular endotypes and recovery trajectories in more than 1,300 trauma patients over time. By analyzing patterns of proteins and metabolites, researchers were able to characterize each patient’s biological response to injury rather than relying solely on physical injury scores.

The results showed that organ failure and mortality could be predicted more accurately and efficiently using omics markers than with traditional injury-based measures. The predictive models achieved 92% accuracy and were validated in an independent cohort of more than 300 trauma patients. The findings, published in Science Translational Medicine, demonstrate that molecular profiling can reveal why patients with similar injuries experience different outcomes, enabling earlier and more precise risk assessment.

Researchers say the approach lays the groundwork for personalized trauma care in real-time emergency settings. Efforts are now underway to adapt the molecular profiling system for rapid, point-of-care testing in emergency departments and military environments. The findings are also expected to influence the design of future clinical trials, including a trial evaluating fibrinogen supplementation. Investigators believe this strategy could support the development of targeted therapies and reshape trauma treatment planning.

"Two patients often arrive in the ER with nearly identical injuries but go on to have widely divergent outcomes despite similar care,” said Mitchell Cohen, senior author and professor of surgery at CU Anschutz. “This occurs because their biologic response to injury and treatment is different. Our novel approach and modeling allows us to see those differences in real time, so we can know their biologic state, predict their trajectories and tailor their treatments in a personalized manner.”

Related Links:
CU Anschutz 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.